Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile

Despite the weak clinical efficacy of TRAIL death receptor agonists, a search is under way for new agents that more efficiently activate apoptotic signaling. We previously created a TRAIL DR5-selective variant DR5-B without affinity for the DR4, DcR1, DcR2, and OPG receptors and increased proapoptot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagolovich, Anne V., Artykov, Artem A., Karmakova, Tatiana A., Vorontsova, Maria S., Pankratov, Andrey A., Andreev-Andrievsky, Alexander A., Dolgikh, Dmitry A., Kirpichnikov, Mikhail P., Gasparian, Marine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110358/
https://www.ncbi.nlm.nih.gov/pubmed/32224450
http://dx.doi.org/10.1016/j.tranon.2020.100762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110358/
https://www.ncbi.nlm.nih.gov/pubmed/32224450
http://dx.doi.org/10.1016/j.tranon.2020.100762

Ejemplares similares